Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet

This article was originally published in The Pink Sheet Daily

Executive Summary

For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.

You may also be interested in...



Third Rock Ventures Rolls Its Own

Third Rock Ventures has raised $1.3 billion by going all-in on early-stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitively that the strategy is working, but then again, its investors just re-upped for a new half-billion-dollar fund.

Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund

The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.

Epigenetics At The Epicenter Of Oncology Drug Discovery At AACR

Epigenetics, an area of biology replete with interesting novel targets and potential for developing drugs that overcome cancer resistance, is a popular topic this year at the American Association for Cancer Research annual meeting, in Washington, D.C., April 6-10.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel